Gotowa bibliografia na temat „Immune check point inhibitor”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Immune check point inhibitor”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Immune check point inhibitor"
Jaswani, Tamika S., Meeta Desai, Douglas Grider i Jonathan M. Bern. "Immune Check Point Inhibitor-induced Colitis". American Journal of Gastroenterology 112 (październik 2017): S858—S860. http://dx.doi.org/10.14309/00000434-201710001-01575.
Pełny tekst źródłaBobart, Shane A., Itunu Owoyemi, Joseph Grande, Nelson Leung i Sandra M. Herrmann. "Immune Check Point Inhibitor–Associated Endothelialitis". Kidney International Reports 5, nr 8 (sierpień 2020): 1371–74. http://dx.doi.org/10.1016/j.ekir.2020.05.027.
Pełny tekst źródłaAshour, Tarek, Georges Nakhoul, Pradnya Patil, Pauline Funchain i Leal Herlitz. "Immune Check Point Inhibitor–Associated Glomerulonephritis". Kidney International Reports 4, nr 2 (luty 2019): 355–59. http://dx.doi.org/10.1016/j.ekir.2018.10.017.
Pełny tekst źródłaKumar, Aswini, Maximilian Lee i Talhat Azemi. "IMMUNE CHECK POINT INHIBITOR MYOCARDITIS MIMICKING ACS". Journal of the American College of Cardiology 73, nr 9 (marzec 2019): 2681. http://dx.doi.org/10.1016/s0735-1097(19)33287-5.
Pełny tekst źródłaNilajgi, Shalini, Nicholas Kasmeridis i Kichendasse Ganessan. "A Case Of Immune Check Point Inhibitor - Induced Hypophysitis". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A560. http://dx.doi.org/10.1210/jendso/bvab048.1142.
Pełny tekst źródłaSuchý, David. "Immune-related adverse events associated with immune check-point inhibitors". Klinická farmakologie a farmacie 33, nr 3 (28.10.2019): 20–24. http://dx.doi.org/10.36290/far.2019.019.
Pełny tekst źródłaMarthey, Lysiane, Raef Abdallah, Christophe Bellanger, Clément Bresteau, Antoine Meyer, Aurélien Amiot i Franck Carbonnel. "Immune check-point inhibitors related enterocolitis". Hépato-Gastro & Oncologie Digestive 30, nr 8 (październik 2023): 826–32. http://dx.doi.org/10.1684/hpg.2023.2641.
Pełny tekst źródłaJohncilla, Melanie, Shilpa Grover, Xuchen Zhang, Dhanpat Jain i Amitabh Srivastava. "Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis". Histopathology 76, nr 4 (18.02.2020): 531–39. http://dx.doi.org/10.1111/his.14029.
Pełny tekst źródłaKim, Jin Young, Chi Heum Cho i Hong Suk Song. "Targeted therapy of ovarian cancer including immune check point inhibitor". Korean Journal of Internal Medicine 32, nr 5 (1.09.2017): 798–804. http://dx.doi.org/10.3904/kjim.2017.008.
Pełny tekst źródłaVergne-Santiago, Norma, Ernesto Jos E. Sola Sanchez i Michelle Marie Mangual Garcia. "Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A136—A137. http://dx.doi.org/10.1210/jendso/bvab048.275.
Pełny tekst źródłaRozprawy doktorskie na temat "Immune check point inhibitor"
Dréan, Raphaelle. "Développement de nano-anticorps antagonistes du point de contrôle immunitaire ILT4 pour une application en immunothérapie antitumorale". Electronic Thesis or Diss., Sorbonne université, 2022. http://www.theses.fr/2022SORUS446.
Pełny tekst źródłaILT4 (Immunoglobulin-Like Transcript 4) is an immune checkpoint receptor mainly expressed by myeloid immune cells. In cancer context, ILT4 participates in tumor development by maintaining a protumoral immuno-microenvironment and directly promoting tumor cell proliferation. ILT4 interaction with the non-classical MCH class I molecule HLA-G induces an immunosuppressive microenvironment by promoting tolerogenic myeloid cells. Moreover, the ectopic expression of ILT4 has been reported in several solid tumors. The activation of ILT4 by Angiopoietin-like-2 (ANGPTL2) promotes non-small cell lung tumor cell proliferation and inhibits cell apoptosis. Targeting this new immune checkpoint with blocking antibodies is therefore a promising cancer immunotherapy approach. In light of several drawbacks of classical IgG blocking antibodies in solid cancer, we investigated the potential of VHH-based inhibitors. This small monoclonal antibody format, derived from camelid homodimeric antibodies, combine the binding capacities of antibodies to the properties of small molecules. After immunization of an alpaca and phage-display screening, we selected a VHH with high affinity and specificity to ILT4 that inhibits the interaction of the receptor with both ligands. We validated the VHH’s biological antagonist activity on tumor cells and monocyte-derived pro-tumoral M2 like macrophages in vitro. These results support the potential of this new VHH-based antibody targeting ILT4 in cancer immunotherapy
Fournel, Ludovic. "Influence Du Cisplatine sur l'expression du Check-Point Immunitaire PD-1/PD-L1 Dans Le Cancer Broncho-Pulmonaire Non A Petites Cellules Cisplatin Increases PD-L1 Expression and Optimizes Immune Check-Point Blockade in Non-Small Cell Lung Cancer Modulation of Lung Cancer Cell Plasticity and Heterogeneity with the Restoration of Cisplatin Sensitivity by Neurotensin Antibody". Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS077.
Pełny tekst źródłaDespite many advances in the recent years in the therapeutic management of bronchopulmonary cancer, it remains the leading cause of death linked to cancer in the world. The major challenge for this disease is therefore to develop new treatments and optimize the use of existing drugs, in particular platinum salts. The number of clinical protocols testing combined therapies including immune check-point inhibitors and platinum salts is currently increasing in lung cancer treatment, however preclinical studies and rationale are often lacking. Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Twenty-two patients exhibited positive PD-L1 staining variation after neoadjuvant chemotherapy; including 9 (23.1%) patients switching from <50% to ≥50% of stained tumor-cells. We also confirmed the up-regulation of PD-L1 by cisplatin, at both RNA and protein levels, in nude and immunocompetent mice bearing tumors grafted with A549, LNM-R, or LLC1 lung cancer cell lines. Up-regulation of PD-L1 by cisplatin involved the PI3K / AKT signaling pathway.The combined administration of anti-PD-L1 antibodies (3mg/kg) and cisplatin (1mg/kg) to mice harboring lung carcinoma significantly reduced tumor growth compared to single agent treatments and controls. Overall, these results suggest that cisplatin treatment could synergize with PD-1/PD-L1 blockade to increase the clinical response, in particular through early and sustainable enhancement of PD-L1 expression. Simultaneously, we were able to develop a targeted anti-neurotensin therapy to block its paracrine effects which stimulate proliferation, growth, and metastatic potential of lung tumor cells. Anti-neurotensin antibodies also improved the sensitivity to cisplatin of previously resistant tumors by mechanisms which probably involve increased influx and decreased efflux of platinum at the intra-nuclear level where resides its target DNA. All of these results provide a rationale for carrying out clinical trials involving cisplatin and aiming, by various ways, to improve the effectiveness of systemic treatments for non-small cell broncho-pulmonary cancers
Grosjean, Iris. "SQSTM1, une protéine de plateforme à la croisée de la réponse aux dommages à l’ADN et de la réponse à l’immunothérapie dans le cancer : rôles des rétrovirus endogènes". Electronic Thesis or Diss., Université Côte d'Azur, 2020. http://www.theses.fr/2020COAZ6037.
Pełny tekst źródłaNon-small cell lung cancer (NSCLC) is the deadliest cancer in the world, due to acquired resistance to genotoxic chemotherapy and radiotherapy (DNA-damaging agents, named DDAs hereafter) and targeted therapies. Immunotherapy (including immune checkpoint inhibitors (ICIs)) is a real revolution in patient care. This strategy has indeed had a positive impact, turning into treatable advanced cancers without "actionable" targets that were considered incurable. Survival at 5-year has increased from 5% with conventional treatment to 20% with immunotherapies and up to 50/60% for melanoma and lung cancer with therapies combining ICIs and DDAs. The current challenge in clinical trials is to develop combined therapeutic strategies that increase efficacy while limiting resistance to different treatments. Elucidating resistance mechanisms is essential to propose new robust predictive biomarkers and new therapeutic approaches to improve the efficacy of ICIs.We have hypothesized that resistance to DDAs and ICIs is mediated by intrinsic tumor mechanisms, some of which may be shared. Thus, we have studied the action of DDAs and their molecular consequences that lead to immune evasion. Through three complementary approaches (in silico, in vivo on patient cohorts and in vitro), we identify the p62/SQSTM1 scaffold protein as a key molecular mediator capable of predicting and controlling sensibility to DDAs and ICIs. We report for the first time that SQSTM1 causes a "HOT" tumor immune profile, while downregulating DNA repair mechanisms. In addition, SQSTM1 is essential for the DDAs-induced reactivation of human endogenous retroviruses (hERVs). Downstream, hERVs induce an innate antiviral response, resulting in the expression of interferons, MHC-I and PD-L1, leading to tumor immune evasion.In conclusion, i) we propose SQSTM1 as a predictive biomarker for selecting patients who may benefit from ICI plus DDA combination strategies, and ii) we highlight a biological rationale for the efficacy of such strategies in refractory lung cancer, aimed at promoting their use and thus improving the prognosis of NSCLC
Munivenkata, Swamy Preethi. "Combined CTLA-4 and PD-1 inhibition a single institute in-depth analysis of toxicity and efficacy in patients treated at the Dana-Farber Cancer Institute". Thesis, 2017. https://hdl.handle.net/2144/26950.
Pełny tekst źródłaCzęści książek na temat "Immune check point inhibitor"
Patel, Anush, Haisam Abid i Amrat Kumar. "The Endocrinological Side Effects of Immunotherapies". W Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96491.
Pełny tekst źródłaThompson, John F., Richard A. Scolyer i Richard F. Kefford. "Skin cancer: melanoma". W Oxford Textbook of Oncology, 674–89. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0049.
Pełny tekst źródłaYadav, Hemang, Alastair C. Carr i Philippe R. Bauer. "Oncological Aspects of Respiratory Critical Care". W Oxford Textbook of Respiratory Critical Care, 437–44. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198766438.003.0049.
Pełny tekst źródłaZekeridou, Anastasia. "“Restlessness” After Cancer Diagnosis and Treatment". W Mayo Clinic Cases in Neuroimmunology, redaktorzy Andrew McKeon, B. Mark Keegan i W. Oliver Tobin, 157–59. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0051.
Pełny tekst źródłaT. Silveira, Fernando, Marliane B. Campos, Silvia F. Müller, Patrícia K. Ramos, Luciana V. Lima, Thiago V. dos Santos, Claudia Maria Gomes, Márcia D. Laurenti, Vania Lucia da Matta i Carlos Eduardo Corbett. "From Biology to Disease: Importance of Species-Specific Leishmania Antigens from the Subgenera Viannia (L. braziliensis) and Leishmania (L. amazonensis) in the Pathogenesis of American Cutaneous Leishmaniasis". W Leishmania Parasites [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.108967.
Pełny tekst źródłaStreszczenia konferencji na temat "Immune check point inhibitor"
Lai, K., V. R. Shannon, D. Balachandran, A. Sheshadri, L. Bashoura i S. A. Faiz. "Role of Infliximab in Immune Check Point Inhibitor Induced Pneumonitis". W American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4736.
Pełny tekst źródłaIbraheim, Hajir, Lavinia Spain, Amit Samani, Sophie Papa, Nadia Yousaf, Martin Gore, James Larkin, Samra Turajlic i Nick Powell. "PWE-025 Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis". W British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.157.
Pełny tekst źródłaAlexander, S. A., V. Mathew Thomas, M. Singh i P. Premkumar. "A Fatal Case of Multisystem Organ Dysfunction Secondary to Immune Check Point Inhibitor Use". W American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1714.
Pełny tekst źródłaHutmacher-Berndt, Cornelia Deborah, i Dario Neri. "Abstract 3811: Targeted Interleukin 2 and synergy with immune check-point inhibitors". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3811.
Pełny tekst źródłaSpain, Lavinia, Amit Samani, Hajir Ibraheim, Lewis Au, Zayd Tippu, Shuai Zhang, Sophie Merrick i in. "PTU-006 Incidence of immune check point inhibitor induced diarrhoea/colitis- experience from a multi-centre cohort". W British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.128.
Pełny tekst źródłaSasikumar, Pottayil G., Leena K. Satyam, Rajeev Shrimali, Raghuveer Ramachandra, Ketha A. Reddy, Adurthi Sreenivas, Amit Dhudashia, Dodderi S. Samiulla i Murali Ramachandra. "Abstract 1231: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway." W Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1231.
Pełny tekst źródłaMitra, D. K., P. Kaur, G. Mehta, A. Mohan i M. Basil. "Immune Check Point Inhibitors in TB Patients: Impact on In-vitro Bacillary Clearance". W American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4870.
Pełny tekst źródłaWong, Chi Wah, Susan E. Yost, Jin Sun Lee, Sarah K. Highlander i Yuan Yuan. "Abstract 336: Gut microbiome predicts response to CDK4/6 inhibitor and immune check point inhibitor combination in patients with hormone receptor positive metastatic breast cancer". W Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-336.
Pełny tekst źródłaMiron Elorriaga, G., Y. Viseda Torrellas, M. Palacios Filardo, M. Cardenas Sierra, FJ Goikolea Ugarte, A. Martin Torrente, L. Torio Alvarez i in. "5PSQ-112 Relationship between effectiveness and immune-mediated toxicity of immune check-point inhibitors in advanced non-small-cell lung cancer". W 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.454.
Pełny tekst źródłaMcKenzie, Andrew, Nektaria Papadopoulou, Simon Jiang, Jane Wrigley, Kelly Jones, Russell Garland, Neil Williams i Rajendra Kumari. "Abstract A140: Check point inhibitor modulation of tumor microenvironment at orthotopic and metastatic sites using bioluminescent syngeneic cell line models in immune competent mice". W Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a140.
Pełny tekst źródła